ClinicalTrials.gg

Program

etentamig

Also written as “Etentamig”, “Etentamig (ABBV-383)” and “ABBV-383 (Etentamig)”.

In AbbVie's pipeline, CD3, BCMA. Its studies are mostly in Multiple Myeloma · Amyloidosis, led by AbbVie.

Furthest: phase 3, since Nov 28, 202311 company-led studies, 11 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie1111 open or runningphase 3since Nov 28, 2023Apr 26, 2019Feb 2027phase 1 · NCT06223516
  • Named in AbbVie’s own pipeline as Etentamig (ABBV-383), phase 4, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 26, 2019First study: phase 2 study in Multiple MyelomaFirst studyNCT03933735 · 220 enrolled · United States, Germany
  2. Mar 17, 2022Phase 1 study in Multiple MyelomaNCT05286229 · 8 enrolled · Japan
  3. Dec 6, 2022Phase 1 study in Multiple MyelomaNCT05650632 · 250 planned · United States, Canada, Denmark and more
  4. Nov 28, 2023Phase 2 study in AmyloidosisNCT06158854 · 76 planned · United States, Australia, France and more
  5. Nov 28, 2023Phase 3 study in Multiple MyelomaNCT06158841 · 421 enrolled · United States, Australia, Austria and more
  6. Jan 17, 2024Phase 1 study in Multiple MyelomaNCT06223516 · 60 enrolled · United States, Germany, Israel and more
  7. Mar 19, 2025Phase 1 study in Multiple MyelomaNCT06896916 · 135 planned · United States, Australia, Canada and more
  8. Mar 19, 2025Phase 2 study in Multiple MyelomaNCT06892522 · 602 planned · United States, Australia, Israel and more
  9. Jul 24, 2025Phase 3 study in Multiple MyelomaNCT07095452 · 680 planned · United States, France, Japan and more
  10. Jul 22, 2026Phase 3 study in RecurrenceNCT07728188 · 520 planned · United States, Australia, Canada and more
  11. Aug 26, 2026Phase 3 study in AmyloidosisNCT07793422 · 370 planned
  12. Oct 19, 2026Primary completion moved from 2040-09 to 2041-03Date moved laterphase 3 · +6 months · NCT07095452

Ahead

  1. Feb 2027Primary completion: phase 1 study in Multiple MyelomaNCT06223516
  2. Dec 2027Primary completion: phase 3 study in Multiple MyelomaNCT06158841
  3. Feb 2028Primary completion: phase 2 study in AmyloidosisNCT06158854
  4. Aug 2029Primary completion: phase 1 study in Multiple MyelomaNCT05650632

TargetBeta

“CD3, BCMA”the company's pipeline, read by Claude · source
“A T-cell engaging, human, bispecific, immunoglobulin G4 (IgG4) monoclonal antibody (T-BsAb) directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and CD3 antigen found on T-lymphocytes, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
teclistamabruleJohnson & Johnsonphase 411
ramantamigJohnson & Johnsonphase 37
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
cizutamigruleUCBphase 25
vonsetamigruleRegeneron Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rulekelonia-therapeutics-incphase 11

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07793422Amyloidosis3Not yet recruitingDec 2034370
NCT07728188Recurrence · United States, Australia, Canada and more3Not yet recruitingFeb 2033520
NCT07095452Multiple Myeloma · United States, France, Japan and more3RecruitingMar 2041680
NCT06896916Multiple Myeloma · United States, Australia, Canada and more1RecruitingMar 2036135
NCT06892522Multiple Myeloma · United States, Australia, Israel and more2RecruitingDec 2035602
NCT06223516Multiple Myeloma · United States, Germany, Israel and more1Active, not recruitingFeb 202760
NCT06158854Amyloidosis · United States, Australia, France and more2RecruitingFeb 202876
NCT06158841Multiple Myeloma · United States, Australia, Austria and more3Active, not recruitingDec 2027421
NCT05650632Multiple Myeloma · United States, Canada, Denmark and more1RecruitingAug 2029250
NCT05286229Multiple Myeloma · Japan1Active, not recruitingMar 20268
NCT03933735Multiple Myeloma · United States, Germany2Active, not recruitingMay 2026220

How it is read

Names in the registry

  • “Etentamig”, 9 entries
  • “Etentamig (ABBV-383)”, 1 entry
  • “ABBV-383 (Etentamig)”, 1 entry
  • “Subcutaneous (SC) Etentamig”, 1 entry
  • “Intravenous (IV) Etentamig”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.